These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 17906702)
41. Prognostic features of multiple myeloma. San Miguel JF; García-Sanz R Best Pract Res Clin Haematol; 2005; 18(4):569-83. PubMed ID: 16026738 [TBL] [Abstract][Full Text] [Related]
43. Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation. Sherman AC; Simonton S; Latif U; Plante TG; Anaissie EJ Biol Blood Marrow Transplant; 2009 Jan; 15(1):12-20. PubMed ID: 19135938 [TBL] [Abstract][Full Text] [Related]
44. New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals. Durie BG Clin Lymphoma Myeloma; 2005 Nov; 6(3):181-90. PubMed ID: 16354323 [TBL] [Abstract][Full Text] [Related]
45. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Heider U; Kaiser M; Mieth M; Lamottke B; Rademacher J; Jakob C; Braendle E; Stover D; Sezer O Eur J Haematol; 2009 Jan; 82(1):31-8. PubMed ID: 19067746 [TBL] [Abstract][Full Text] [Related]
46. In pursuit of the allo-immune response in multiple myeloma: where do we go from here? Cook G; Bird JM; Marks DI Bone Marrow Transplant; 2009 Jan; 43(2):91-9. PubMed ID: 19079310 [TBL] [Abstract][Full Text] [Related]
47. Myelosuppression associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Miceli T; Colson K; Gavino M; Lilleby K; Clin J Oncol Nurs; 2008 Jun; 12(3 Suppl):13-20. PubMed ID: 18490253 [TBL] [Abstract][Full Text] [Related]
48. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. El-Cheikh J; Michallet M; Nagler A; de Lavallade H; Nicolini FE; Shimoni A; Faucher C; Sobh M; Revesz D; Hardan I; Fürst S; Blaise D; Mohty M Haematologica; 2008 Mar; 93(3):455-8. PubMed ID: 18287132 [TBL] [Abstract][Full Text] [Related]
49. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968 [TBL] [Abstract][Full Text] [Related]
50. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. Kumar SK; Dingli D; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA Bone Marrow Transplant; 2008 Jun; 41(12):1013-9. PubMed ID: 18332915 [TBL] [Abstract][Full Text] [Related]
51. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Hainsworth JD; Spigel DR; Barton J; Farley C; Schreeder M; Hon J; Greco FA Cancer; 2008 Aug; 113(4):765-71. PubMed ID: 18543319 [TBL] [Abstract][Full Text] [Related]